CO07 | Real word management of anticoagulant therapy in brain metastasis: moving toward a multidisciplinary approach in complex cases
E. Lotti1, C. Manneschi2, S. Fancelli2, F. Scolari1, F. Crudele1, D. Poli1, M. Berteotti1, D. Rossini3, S. Pillozzi2, L. Antonuzzo2,3, R. Marcucci1,3 | 1Disease Unit, Careggi University Hospital, Firenze; 2Oncology Unit, Careggi University Hospital, Firenze; <sup>3</sup>Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Patients with advanced solid tumors have an increased risk of thrombosis and are often on anticoagulation treatment with low molecular weight heparin (LMWH) or the new oral anticoagulant drugs (DOACs). Brain metastases (BMs) have an increased risk of intracranial bleeding (ICH), depending on systemic and locoregional treatments. However, existing literature consists of small case series, and prospective studies of LMWH and DOACs do not include BMs’ patients. Our study aims to describe the impact of adverse events related to anticoagulant therapy, in a real word setting in patients with BMs.
Method: We retrospectively collected data of oncological patients with BMs treated between 2015 and 2024 followed by the Oncology Unit and the Atherothrombotic Disease Unit at Careggi University Hospital.
Results: We enrolled 301 patients with BMs; of these, 155 were treated mainly with LMWH (58.1%) or DOACs (24.5%). Among patients who received anticoagulant therapy, 25 patients developed treatment-related complications. In particular,10 patients (6.4%) experienced a thrombotic adverse event (AE), 12 patients (7.8%) experienced a hemorrhagic AE, and 3 patients (2.1%) experienced both complications. Of the 15 major hemorrhagic events, 6 occurred in the brain, 4 of which were intracranial. There was no significant difference in bleeding or thrombosis incidence between the LMWH and DOAC groups (p=0.57). However, the time to onset of bleeding was three times longer than the time to onset of thrombosis (3.8 [95% CI 0-151.6] vs. 1.3 [95% CI 0-136.4]; p=0.37).
Conclusions: Cancer patients with BMs have an increased risk of thrombosis, requiring anticoagulant treatment. DOAC therapy does not appear to increase the risk of bleeding. A multi-discipline approach is essential to best manage anticoagulant therapy allowing to be tailored to the individual patients bleeding risk.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- Marco Cattaneo, Guided antiplatelet therapy in patients undergoing percutaneous coronary intervention , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Francesca Santilli, Paola Simeone, Rossella Liani, Inflammation, platelets and diabetes , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- PO18 | Does muscle mass matter? Appendicular lean mass as a determinant of anti-XA activity in elderly patientes , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Paolo Prandoni, Franca Bilora, Raffaele Pesavento, Giorgina Salgueiro, Angeles Blanco-Molina, Raquel Lòpez-Reyes, Manuel Monreal, and the RIETE Investigators, Treatment of venous thromboembolism in pregnancy: findings from the RIETE Registry , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Marcello Baroni, Paolo Ferraresi, Nicole Ziliotto, Daria Bortolotti, Pierfilippo Acciarri, Nicola Martinelli, Giovanna Marchetti, Matteo Coen, Francesco Bernardi, Protein S on the surface of plasma lipoproteins: a potential mechanism for protein S delivery to the atherosclerotic plaques? , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- CS03 | Khorana risk score and genomic profiling for prediction of venous thromboembolism in ovarian cancer , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO16 | Antithrombotic treatment and outcomes in retinal vein occlusion: a retrospective cohort study and comparison with historical group , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO01 | Statin therapy for the prevention of venous thromboembolism in cancer patients: a systematic review and meta-analysis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Anna Poretto, Elisabetta Borella, Giacomo Turatti, Michelangelo Marobin, Elena Campello, Daniela Tormene, Paolo Simioni, Luca Spiezia, Association between non-O blood type and early unexplained recurrent spontaneous abortion in women with and without inherited thrombophilia , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Setor K. Kunutsor, Sudhir Kurl, Ari Voutilainen, Jari Laukkanen, Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
You may also start an advanced similarity search for this article.
